Flamel Technologies (AVDL) Receiving Somewhat Favorable News Coverage, Accern Reports
News articles about Flamel Technologies (NASDAQ:AVDL) have been trending somewhat positive on Friday, Accern Sentiment reports. Accern rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Flamel Technologies earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 47.3455072765598 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
AVDL has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded Flamel Technologies from a “strong-buy” rating to a “hold” rating in a report on Friday, May 12th. Roth Capital set a $15.00 price target on Flamel Technologies and gave the stock a “buy” rating in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating and three have issued a buy rating to the company. Flamel Technologies presently has an average rating of “Buy” and an average target price of $14.75.
Shares of Flamel Technologies (NASDAQ AVDL) traded down 1.40% during mid-day trading on Friday, hitting $9.16. The stock had a trading volume of 42,463 shares. The firm has a market capitalization of $367.17 million, a price-to-earnings ratio of 9.67 and a beta of 1.37. The stock’s 50-day moving average is $9.63 and its 200 day moving average is $9.91. Flamel Technologies has a 1-year low of $8.14 and a 1-year high of $14.70.
Flamel Technologies (NASDAQ:AVDL) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.14. Flamel Technologies had a net margin of 21.13% and a return on equity of 29.84%. The company had revenue of $46.30 million during the quarter, compared to analyst estimates of $45.17 million. The business’s revenue was up 19.0% compared to the same quarter last year. Equities research analysts predict that Flamel Technologies will post $1.13 EPS for the current fiscal year.
In related news, major shareholder Healthcare Master Fun Broadfin sold 261,000 shares of Flamel Technologies stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $10.68, for a total transaction of $2,787,480.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Guillaume Cerutti sold 26,560 shares of Flamel Technologies stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $10.46, for a total transaction of $277,817.60. Following the sale, the director now owns 23,440 shares of the company’s stock, valued at approximately $245,182.40. The disclosure for this sale can be found here. Company insiders own 5.07% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Flamel Technologies (AVDL) Receiving Somewhat Favorable News Coverage, Accern Reports” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/25/flamel-technologies-avdl-receiving-somewhat-favorable-news-coverage-accern-reports.html.
Flamel Technologies Company Profile
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.
Receive News & Stock Ratings for Flamel Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies S.A. and related stocks with our FREE daily email newsletter.